Rhinitis/rhinorrhea (Intranasal Products)
The researchers found that the budesonide group had a mean score on the Sino-Nasal Outcome Test (SNOT-22) that was 7 points better (95% confidence interval, −2 to 16) than the control group.
Because determining an appropriate treatment plan for a patient depends on the subtype of the disease, it is imperative for providers to know and understand the underlying mechanisms of CRS as well as the components included in a medical evaluation of a patient.
Fluticasone Propionate Nasal Spray is a corticosteroid indicated for the management of the nasal symptoms of perennial nonallergic rhinitis in adults and pediatric patients aged 4 years and older.
A total of 27 articles were identified. Of these, 6 evaluated symptoms, 9 assessed QOL, 5 studied daily activities, 3 evaluated emotional aspects, 6 assessed sleep, 7 studied education, and 2 evaluated treatment burden.
The researchers found that just under two-thirds of customers (63.2%) had a doctor's diagnosis for the symptoms for which they were selecting treatment. The majority of participants (70%) self-selected their medications.
The Sinuva Sinus Implant is a corticosteroid-eluting (mometasone furoate) implant indicated for the treatment of nasal polyps.
FlutiCare will be available OTC with the same prescription strength and same delivery method as Flonase and ClariSpray.
Significant differences were identified in PT seconds for the control group versus the moderate and severe OSA groups (mean, 11.26 versus 10.74 and 10.67, respectively).
"In conclusion, the capsaicin nasal spray is effective in a broader group of IR than the purely selected ones described before," the authors wrote.
The Sinuva implant releases mometasone furoate to the ethmoid sinus lining and is intended to treat chronic sinusitis patients who have recurrent sinus obstruction.
The authors note that diagnosis of NAR is based on a detailed medical history and exclusion of clinically relevant sensitization to airborne allergens, and exclusion of clinical signs of rhinosinusitis.
Receiver operating curve analyses showed moderate and high diagnostic accuracy for detecting chronic rhinosinusitis and chronic rhinosinusitis with nasal polyps, respectively.
GSK Consumer Healthcare announced the availability of Flonase Sensimist Allergy Relief (fluticasone furoate), an over-the-counter (OTC) treatment for symptoms associated with seasonal and perennial allergies for patients aged ≥12 years.
Programmed cell death 1 (PD-1) expression is associated with chronic rhinosinusitis with nasal polyps (CRSwNP) disease severity, according to a study published online in Allergy.
Verapamil, a calcium channel blocker, has shown significant efficacy in alleviating symptoms of patients with chronic rhinosinusitis (CRS) with nasal polyps.